Drugs

Jun 19, 2025, 15:30

Graham Collins: Nivo-AVD vs BV-AVD in Older Patients (60+) with Hodgkin Lymphoma

Graham Collins, Associate Professor, Haematology and lymphoma specialist at Oxford Cancer and Haematology centre, shared a post on X:

“Nivo-AVD vs BV-AVD in older pts (60+) with Hodgkin. S1826 data. 99 eligible pts. 2y PFS
• 89% Nivo-AVD
• 64% BV-AVD
55% discontinued BV, 14% Nivo
NRM 16% BV-AVD, 6% Nivo-AVD
Transformational. If only we had access.”

Title: Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

Authors: Sarah C. Rutherford, Hongli Li, Alex F. Herrera, Michael LeBlanc, Sairah Ahmed, Kelly Davison, Susan K. Parsons, Joseph M. Unger, Anamarija M. Perry, Carla Casulo, Nancy L. Bartlett, Joseph M. Tuscano, Brian T. Hess, Pallawi Torka, Pankaj Kumar, Ryan Jacobs, Joo Y. Song, Sharon M. Castellino, Brad Kahl, John P. Leonard, Sonali M. Smith, Jonathan W. Friedberg, Andrew M. Evens

Read Full Article.

Nivo-AVD vs BV-AVD

More Posts Featuring Hodgkin Lymphoma on OncoDaily.

Alex F. Herrera Anamarija M. Perry Andrew M. Evens Brad Kahl Brian T. Hess cancer Carla Casulo Graham Collins Hongli Li John P. Leonard Jonathan W. Friedberg Joo Y. Song Joseph M. Tuscano Joseph M. Unger Kelly Davison Michael LeBlanc Nancy L Bartlett OncoDaily Oncology Pallawi Torka Pankaj Kumar Ryan Jacobs Sairah Ahmed Sarah C. Rutherford Sharon M. Castellino Sonali M. Smith Susan K. Parsons

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Top 5 AI Tools for Radiation Oncologists: What Clinicians Need to Know

FDA Grants Accelerated Approval to Sunvozertinib for EGFR Exon 20 Insertion Mutations in NSCLC

Uhm Jung-hwa: Korea’s Iconic ‘Madonna’ and Her Triumphant Battle Against Thyroid Cancer

Vincent Rajkumar: A Historic Day for High Risk Smoldering Myeloma